 SAN FRANCISCO, May 20, 2021 PRNewswire -- Hagens Berman urges Iovance Biotherapeutics, Inc. NASDAQ: IOVA investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. 